Literature DB >> 28274510

Can contrast-enhanced MRI with gadoxetic acid predict liver failure and other complications after major hepatic resection?

A F Costa1, A Tremblay St-Germain2, M Abdolell2, R L Smoot2, S Cleary2, K S Jhaveri3.   

Abstract

AIM: To determine whether a combination of clinical factors, the future liver remnant (FLR) ratio, and hepatic uptake of gadoxetic acid can be used to predict post-hepatectomy liver failure (PHLF) and other major complications (OMC).
MATERIALS AND METHODS: Sixty-five consecutive patients who underwent pre-hepatectomy gadoxetic acid-enhanced magnetic resonance imaging (MRI) between October 2010 and December 2013 were included. The relative liver enhancement (RLE) of gadoxetic acid was calculated from regions of interest on MRI, and FLR ratios were obtained from computed tomography (CT). PHLF and OMC were defined by the International Study Group of Liver Surgery criteria and Clavien-Dindo grade of ≥3, respectively. Multivariate logistic regression modelling was performed to identify predictors of PHLF and OMC, including RLE, FLR ratio, age, sex, chemotherapy history, intra-operative blood loss, and intra-operative transfusion.
RESULTS: Nine patients experienced PHLF and another nine patients experienced OMC. RLE was comparable to the FLR ratio in predicting PHLF (areas under the receiver operating characteristic [AUROC] curves, 0.665 and 0.705), but performed poorly in predicting OMCs (AUROCs, 0.556 and 0.702). Combining all clinical and imaging parameters as predictors yielded the best performing predictive models (AUROCs, 0.875 and 0.742 for PHLF and OMC, respectively).
CONCLUSION: A model based on clinical parameters, the FLR ratio, and RLE of gadoxetic acid may improve pre-hepatectomy risk assessment.
Copyright © 2017 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28274510     DOI: 10.1016/j.crad.2017.02.004

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  7 in total

Review 1.  Advances in functional and molecular MRI technologies in chronic liver diseases.

Authors:  Iris Y Zhou; Onofrio A Catalano; Peter Caravan
Journal:  J Hepatol       Date:  2020-06-22       Impact factor: 25.083

2.  Predictive value of combined computed tomography volumetry and magnetic resonance elastography for major complications after liver resection.

Authors:  Kazu Shibutani; Masahiro Okada; Jitsuro Tsukada; Kenji Ibukuro; Hayato Abe; Naoki Matsumoto; Yutaka Midorikawa; Mitsuhiko Moriyama; Tadatoshi Takayama
Journal:  Abdom Radiol (NY)       Date:  2021-03-08

3.  Advanced liver imaging using MR to predict outcomes in chronic liver disease: a shift from morphology to function liver assessment.

Authors:  Francesco Verde; Valeria Romeo; Simone Maurea
Journal:  Quant Imaging Med Surg       Date:  2020-03

4.  Hepatic function assessment to predict post-hepatectomy liver failure: what can we trust? A systematic review.

Authors:  Federico Tomassini; Mariano C Giglio; Giuseppe De Simone; Roberto Montalti; Roberto I Troisi
Journal:  Updates Surg       Date:  2020-08-04

Review 5.  Update on Liver Failure Following Hepatic Resection: Strategies for Prediction and Avoidance of Post-operative Liver Insufficiency.

Authors:  Amir A Rahnemai-Azar; Jordan M Cloyd; Sharon M Weber; Mary Dillhoff; Carl Schmidt; Emily R Winslow; Timothy M Pawlik
Journal:  J Clin Transl Hepatol       Date:  2017-11-30

Review 6.  Quantification of liver function using gadoxetic acid-enhanced MRI.

Authors:  Sarah Poetter-Lang; Nina Bastati; Alina Messner; Antonia Kristic; Alexander Herold; Jacqueline C Hodge; Ahmed Ba-Ssalamah
Journal:  Abdom Radiol (NY)       Date:  2020-10-09

7.  Hepatocellular uptake index obtained with gadoxetate disodium-enhanced magnetic resonance imaging in the assessment future liver remnant function after major hepatectomy for biliary malignancy.

Authors:  T Notake; A Shimizu; K Kubota; T Ikehara; H Hayashi; K Yasukawa; A Kobayashi; A Yamada; Y Fujinaga; Y Soejima
Journal:  BJS Open       Date:  2021-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.